BRIEF-Five Prime Therapeutics presents preclinical research data on csf-1r and pd-1 blockade
April 3 Five Prime Therapeutics Inc:
* Five Prime Therapeutics Inc says presents preclinical research data on csf-1r and pd-1 blockade
* Five Prime -results show that, when added to pd-1/pd-l1 blockade, surrogate antibody for fpa008 can significantly enhance anti-tumor efficacy Source text for Eikon: Further company coverage: